Based on the Sanofi stock forecast from 1 analysts, the average analyst target price for Sanofi is USD 80.00 over the next 12 months. Sanofi’s average analyst rating is Sell. Stock Target Advisor’s own stock analysis of Sanofi is Slightly Bearish, which is based on 5 positive signals and 7 negative signals. At the last closing, Sanofi’s stock price was USD 94.25. Sanofi’s stock price has changed by +2.31% over the past week, +0.57% over the past month and -15.47% over the last year.
No recent analyst target price found for Sanofi
No recent average analyst rating found for Sanofi
Company Overview Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France. Read Less
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides special...Read More
Frequently Asked Questions About Sanofi (SNYNF) Stock
SNYNF stock's dividend yield is 4.33%.
Our analysis grades SNYNF stock's dividend yield at B. This means that SNYNF stock's dividend yield is above 83% of the stocks in the Drug Manufacturers - General sector in the OTC exchange.
Based on this SNYNF may be a good dividend stock for its sector.
Based on targets from 1 analysts, the average taret price for SNYNF is USD 80.00 over the next 12 months. The maximum analyst target price is USD 80 while the minimum anlayst target price is USD 80.
SNYNF stock's Price/Earning ratio is 19.94.
Our analysis grades SNYNF stock's Price / Earning ratio at D-. This means that SNYNF stock's Price/Earning ratio is above 38% of the stocks in the Drug Manufacturers - General sector in the OTC exchange.
Based on this SNYNF may be fairly valued for its sector
The last closing price of SNYNF's stock was USD 94.25.
The most recent market capitalization for SNYNF is USD 119.74B.
Based on targets from 1 analysts, the average taret price for SNYNF is projected at USD 80.00 over the next 12 months.
This means that SNYNF's stock price may go down by -15.12% over the next 12 months.
Following are ETFs with the highest allocation to Sanofi's stock :
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SNYNF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
